Novel Insights for Improving the Therapeutic Safety and Efficiency of Mesenchymal Stromal Cells

Overview

Journal World J Stem Cells

Publisher Baishideng Publishing Group

Date 2021 Jan 28

PMID 33505596

Citations 8

Authors

Mehdi Najar

Johanne Martel-Pelletier

Jean Pierre Pelletier

Hassan Fahmi

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stromal cells (MSCs) have attracted great interest in the field of regenerative medicine. They can home to damaged tissue, where they can exert pro-regenerative and anti-inflammatory properties. These therapeutic effects involve the secretion of growth factors, cytokines, and chemokines. Moreover, the functions of MSCs could be mediated by extracellular vesicles (EVs) that shuttle various signaling messengers. Although preclinical studies and clinical trials have demonstrated promising therapeutic results, the efficiency and the safety of MSCs need to be improved. After transplantation, MSCs face harsh environmental conditions, which likely dampen their therapeutic efficacy. A possible strategy aiming to improve the survival and therapeutic functions of MSCs needs to be developed. The preconditioning of MSCs would strength their capacities by preparing them to survive and to better function in this hostile environment. In this review, we will discuss several preconditioning approaches that may improve the therapeutic capacity of MSCs. As stated above, EVs can recapitulate the beneficial effects of MSCs and may help avoid many risks associated with cell transplantation. As a result, this novel type of cell-free therapy may be safer and more efficient than the whole cell product. We will, therefore, also discuss current knowledge regarding the therapeutic properties of MSC-derived EVs.

Citing Articles

Replicative senescence in amniotic fluid-derived mesenchymal stem cells and its impact on their immunomodulatory properties.

Zare E, Hosseini E, Azad F, Javid A, Javazm R, Abessi P Histochem Cell Biol. 2025; 163(1):34.

PMID: 40042688 DOI: 10.1007/s00418-025-02364-7.

The Immunological Profile of Adipose Mesenchymal Stromal/Stem Cells after Cell Expansion and Inflammatory Priming.

Buyl K, Merimi M, Rodrigues R, Rahmani S, Fayyad-Kazan M, Bouhtit F Biomolecules. 2024; 14(7).

PMID: 39062566 PMC: 11275169. DOI: 10.3390/biom14070852.

Priming mesenchymal stem cells to develop "super stem cells".

Haider K World J Stem Cells. 2024; 16(6):623-640.

PMID: 38948094 PMC: 11212549. DOI: 10.4252/wjsc.v16.i6.623.

The Promising Role of a Zebrafish Model Employed in Neural Regeneration Following a Spinal Cord Injury.

Zeng C, Tsai H Int J Mol Sci. 2023; 24(18).

PMID: 37762240 PMC: 10530783. DOI: 10.3390/ijms241813938.

The Medicinal Potential of Mesenchymal Stem/Stromal Cells in Immuno- and Cancer Therapy.

Najar M, Fahmi H, Merimi M Biomolecules. 2023; 13(8).

PMID: 37627236 PMC: 10452446. DOI: 10.3390/biom13081171.

References

Liang B, Liang J, Ding J, Xu J, Xu J, Chai Y . Dimethyloxaloylglycine-stimulated human bone marrow mesenchymal stem cell-derived exosomes enhance bone regeneration through angiogenesis by targeting the AKT/mTOR pathway. Stem Cell Res Ther. 2019; 10(1):335. PMC: 6869275. DOI: 10.1186/s13287-019-1410-y. View

Martin-Rufino J, Espinosa-Lara N, Osugui L, Sanchez-Guijo F . Targeting the Immune System With Mesenchymal Stromal Cell-Derived Extracellular Vesicles: What Is the Cargo's Mechanism of Action?. Front Bioeng Biotechnol. 2019; 7:308. PMC: 6856662. DOI: 10.3389/fbioe.2019.00308. View

Garcia J, Quiros M, Han W, OLeary M, Cox G, Nusrat A . IFN-γ-tethered hydrogels enhance mesenchymal stem cell-based immunomodulation and promote tissue repair. Biomaterials. 2019; 220:119403. PMC: 6717550. DOI: 10.1016/j.biomaterials.2019.119403. View

Wang G, Cao K, Liu K, Xue Y, Roberts A, Li F . Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells. Cell Death Differ. 2017; 25(7):1209-1223. PMC: 6030103. DOI: 10.1038/s41418-017-0006-2. View

Saldana L, Bensiamar F, Valles G, Mancebo F, Garcia-Rey E, Vilaboa N . Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors. Stem Cell Res Ther. 2019; 10(1):58. PMC: 6375172. DOI: 10.1186/s13287-019-1156-6. View

Li Y, Lin F . Mesenchymal stem cells are injured by complement after their contact with serum. Blood. 2012; 120(17):3436-43. PMC: 3482856. DOI: 10.1182/blood-2012-03-420612. View

Michael S, Achilleos C, Panayiotou T, Strati K . Inflammation Shapes Stem Cells and Stemness during Infection and Beyond. Front Cell Dev Biol. 2016; 4:118. PMC: 5089974. DOI: 10.3389/fcell.2016.00118. View

Rosova I, Dao M, Capoccia B, Link D, Nolta J . Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells. 2008; 26(8):2173-82. PMC: 3017477. DOI: 10.1634/stemcells.2007-1104. View

Zhao L, Hu C, Zhang P, Jiang H, Chen J . Melatonin preconditioning is an effective strategy for mesenchymal stem cell-based therapy for kidney disease. J Cell Mol Med. 2019; 24(1):25-33. PMC: 6933322. DOI: 10.1111/jcmm.14769. View

10.

Guerrouahen B, Sidahmed H, Al Sulaiti A, Al Khulaifi M, Cugno C . Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System. Stem Cells Int. 2019; 2019:7219297. PMC: 6701346. DOI: 10.1155/2019/7219297. View

11.

Najar M, Ouhaddi Y, Bouhtit F, Melki R, Afif H, Boukhatem N . Empowering the immune fate of bone marrow mesenchymal stromal cells: gene and protein changes. Inflamm Res. 2018; 68(2):167-176. DOI: 10.1007/s00011-018-1198-8. View

12.

Raicevic G, Rouas R, Najar M, Stordeur P, Boufker H, Bron D . Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum Immunol. 2009; 71(3):235-44. DOI: 10.1016/j.humimm.2009.12.005. View

13.

Silveira G, Ishimura M, Teixeira D, Galindo L, Sardinha A, Porcionatto M . Improvement of Mesenchymal Stem Cell Immunomodulatory Properties by Heat-Killed via TLR2. Front Mol Neurosci. 2019; 11:489. PMC: 6336115. DOI: 10.3389/fnmol.2018.00489. View

14.

Kock J, Rodrigues R, Branson S, Verhoye L, Colemonts-Vroninks H, Rombaut M . Inflammation Alters the Secretome and Immunomodulatory Properties of Human Skin-Derived Precursor Cells. Cells. 2020; 9(4). PMC: 7226778. DOI: 10.3390/cells9040914. View

15.

Basmaeil Y, Rashid M, Khatlani T, Alshabibi M, Bahattab E, Abdullah M . Preconditioning of Human Decidua Basalis Mesenchymal Stem/Stromal Cells with Glucose Increased Their Engraftment and Anti-diabetic Properties. Tissue Eng Regen Med. 2020; 17(2):209-222. PMC: 7105536. DOI: 10.1007/s13770-020-00239-7. View

16.

Zoehler B, Fracaro L, Senegaglia A, da Graca Bicalho M . Infusion of Mesenchymal Stem Cells to Treat Graft Versus Host Disease: the Role of HLA-G and the Impact of its Polymorphisms. Stem Cell Rev Rep. 2020; 16(3):459-471. DOI: 10.1007/s12015-020-09960-1. View

17.

Witwer K, van Balkom B, Bruno S, Choo A, Dominici M, Gimona M . Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019; 8(1):1609206. PMC: 6493293. DOI: 10.1080/20013078.2019.1609206. View

18.

Loebel C, Burdick J . Engineering Stem and Stromal Cell Therapies for Musculoskeletal Tissue Repair. Cell Stem Cell. 2018; 22(3):325-339. PMC: 5834383. DOI: 10.1016/j.stem.2018.01.014. View

19.

Sobacchi C, Palagano E, Villa A, Menale C . Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate. Front Bioeng Biotechnol. 2017; 5:32. PMC: 5434159. DOI: 10.3389/fbioe.2017.00032. View

20.

Najar M, Raicevic G, Jebbawi F, De Bruyn C, Meuleman N, Bron D . Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett. 2012; 146(1-2):50-6. DOI: 10.1016/j.imlet.2012.04.017. View